Objective: Obesity is a common comorbid condition among patients with fibromyalgia (FM). Our objective was to assess if obesity moderates the treatment benefits of exercise-based motivational interviewing (MI) for FM.
F ibromyalgia (FM) is a highly prevalent chronic pain disorder characterized by a wide range of disabling symptoms, including fatigue, anxiety, cognitive impairment, and reduced physical functioning. 1, 2 The complex clinical presentation of the disorder often complicates the diagnosis and treatment approach for clinicians, since many patients also present with a myriad of comorbid chronic conditions (eg, sleep disorders, depression, hypertension, and type 2 diabetes). 3, 4 As the disorder worsens, many patients experience a progressive decline in physical activity, 5 which likely contributes to excessive weight gain and worsening pain symptoms. 6, 7 Obesity is one of the most consistent comorbid conditions among patients with FM. [8] [9] [10] The pathways linking chronic pain and obesity are multifactorial, involving both physiological and psychological mechanisms. 11 Nevertheless, the available research is persuasive that obesity has a powerful and independent influence on pain in patients with FM. Compared with the normal weight patients with FM, overweight and obese patients with FM report greater pain severity, reduced physical function, higher levels of depression and anxiety, worse sleep quality, and poorer quality of life. 8, 10, 12, 13 In addition, there is evidence to suggest that having a higher body mass index (BMI) negatively impacts exercise and physical activity participation, which in turn, often worsens the impact of the disorder. 13 Given that obesity has been implicated as a barrier to pain management, 14 and similarly, pain is often described as a barrier to weight loss, 15 it is plausible to suggest that weight status may be a key moderator in the successful management of FM symptomatology.
Despite accumulating evidence linking obesity and pain, relatively few studies have investigated the influence of obesity on treatment interventions in the chronic pain populations. [16] [17] [18] Sellinger et al 18 initially raised the hypothesis that obesity was associated with poor treatment outcomes, reporting that cognitive behavioral therapy was less effective in treating chronic low back pain in patients with comorbid obesity. However, no randomized controlled studies have examined the impact of obesity on the outcomes of psychological interventions for FM. Motivational interviewing (MI) is a person-centered approach that aims to resolve an individual's ambivalence about, and improve adherence to, a specific behavior change. 19 MI has shown success in modifying several health risk behaviors (eg, weight loss and physical inactivity) 20, 21 and may be a useful approach for improving treatment adherence in chronic pain conditions. 22 However, the moderating role of obesity in MI treatment effectiveness has not been tested.
The Research to Encourage Exercise for Fibromyalgia (REEF) study was a randomized clinical trial to evaluate the efficacy of MI to encourage a more physically active lifestyle in patients with FM to improve FM-relevant clinical outcomes. 23 In this study, the beneficial effects of MI on physical activity and clinical outcomes were evident immediately postintervention, but not at the 6-month follow-up. For this secondary analysis, data from the REEF study were used to address the question of whether obesity moderates MI-based treatment outcomes in patients with FM. We hypothesized that there was a significant interaction between obesity and treatment groups; specifically, that the long-term effect of MI on global FM symptom severity (as measured by Fibromyalgia Impact Questionnaire [FIQ]) will be attenuated in the presence of coexisting obesity.
MATERIALS AND METHODS

Experimental Design
Details of the REEF study design, inclusion and exclusion criteria, and measurement protocols have been described elsewhere. 24 Briefly, following randomization to either the MI intervention group or attention control (AC) group (and before the MI counseling phase of the study), each patient received an individualized exercise prescription and 2 supervised exercise sessions. After completing both exercise sessions, participants received either 6 exercisebased (MI) or 6 FM-related health education (AC) telephone calls over the following 12 weeks. To evaluate the long-term effects of MI, phone calls (both groups) were discontinued at week 12 and follow-up assessments of our outcome measures were conducted at week 12 (immediate postintervention), week 24 (3-month follow-up), and week 36 (6-month follow-up). The study was approved by the Indiana University Institutional Review Board in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
Study Participants
Patients invited to participate were referred from specialty (rheumatology, neurology, pain management) or primary care clinics with an initial diagnosis of FM. Eligibility requirements included the following: (1) male or female between 18 and 65 years old; (2) 1990 American College of Rheumatology classification criteria for FM 25 ; and (3) Brief Pain Inventory (BPI) pain intensity score Z4. 26 The exclusion criteria were: known cardiovascular or pulmonary disease, any musculoskeletal or neurological disorders that would preclude moderate-intensity exercise, other inflammatory rheumatic conditions (eg, rheumatoid arthritis, systemic lupus, or other connective tissue disease), participation in moderate-vigorous physical activity on Z3 days a week during the previous 6 months, and treatment with drugs affecting the chronotropic response to exercise (eg, b-blockers). Complete details of participant recruitment, including inclusion/exclusion criteria have been described previously. 24 
Exercise Training Program
Both MI and AC participants received 2 supervised exercise sessions and an individualized exercise prescription that included the initial exercise frequency (2 to 3 d/wk), intensity (40% to 50% of heart rate reserve), and duration (10 to 12 min/session), as well as the progression of the exercise program over the succeeding 36 weeks. All participants were instructed to gradually increase their total volume of exercise to a maximum of 55% to 65% of heart rate reserve, 28 to 30 min/session, and 3 to 4 d/wk over the ensuing 36 weeks. 23 
Primary Outcome Measure
The FIQ is a reliable, validated self-administered questionnaire designed to assess overall symptom burden in patients with FM. 27 The FIQ contains 10 subscales (score range, 0 to 10), which are summed to yield the total FIQ score (FIQ). Higher score on the FIQ indicates a greater overall symptom burden on the individual.
Secondary Outcome Measures
Pain intensity was assessed with the BPI, a self-report questionnaire designed to assess the severity and overall impact of pain. The BPI rates pain severity on 4 items (current, worst, least, and average pain in past week). 26 The BPI has been proven reliable, valid, and responsive to change in patients with chronic noncancer pain. 28 Depression severity was assessed with the Patient Health Questionnaire 8-item Depression Scale (PHQ-8), a brief, selfadministered questionnaire designed to assess major depressive disorder symptoms. The PHQ-8 allows a score (range, 0 to 24) based on the total number and severity of depressive symptoms reported over the previous 2 weeks. 29 Physical activity was assessed with the Community Healthy Activities Model Program for Seniors (CHAMPS), a self-report questionnaire that asks about the frequency, intensity, and duration of physical activity usually performed during a typical week over the previous 4 weeks. In older adults, CHAMPS has demonstrated content and construct validity, internal consistency, and responsiveness to change. 30 CHAMPS was used in the current study due to its ability to capture a wide range of physical activities, including household, occupational, daily tasks, and exercise. The time spent in light-moderate physical activity was calculated in accordance with the original scoring instructions for the CHAMPS questionnaire. 31 The 6-Minute Walk Test (6MWT) is a clinically relevant measure of aerobic exercise capacity that is reproducible, sensitive to change, and significantly related to the FIQ score in patients with FM. 32, 33 For this study, the 6MWT was performed indoors on a 30-meter flat surface consistent with guidelines recommended by the American Thoracic Society. 34 Each participant completed the 6MWT at study entry (baseline), immediate postintervention (week 12), and at the 6-month follow-up (week 36).
Statistical Analyses
BMI values were used to categorize participants as either obese (BMIZ30 kg/m 2 ) or nonobese (BMI < 30 kg/ m 2 ). Mixed linear models were used to analyze the data, to determine whether there were significant interactions between treatment groups and obesity. Mixed linear models allow for the addition of covariates, as well as the use of the appropriate covariance structure. The general model utilized a 2 Â2 factorial model, with 2 treatment groups (MI and AC) and 2 BMI categories (< 30 and 30 +), and the inclusion of an interaction term and adjustment for baseline values of the variables of interest. This method also allows for the analysis of within group differences (ie, comparing treatment groups within BMI categories) while keeping the error rate from becoming inflated. All analytic assumptions were verified and all analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Of the 996 patients screened for participation in the study, 216 (22%) met the inclusion criteria and were randomized to MI (n = 107) and AC (n = 109). Of these, 198 had complete data at last follow-up visit (retention rate = 91.6%) and were included for analyses. Baseline characteristics were similar across treatment groups on all variables (P > 0.20), except BMI. Compared with the AC group, participants in the MI group were slightly heavier (32.49 ± 7.60 vs. 30.73 ± 6.65; P = 0.08). Descriptive data for all participants are presented in Table 1 .
Baseline characteristics also were similar across BMI categories, except for depression (PHQ-8) and aerobic endurance capacity (6MWT). Compared with the nonobese group (n = 91; 46%), those in the obese subset (n = 107; 54%) had higher PHQ-8 scores (13.17 ± 5.12 vs. 11.49 ± 4.57; P = 0.02) and walked a shorter distance during the 6MWT (465.8 ± 68.84 vs. 508.1 ± 82.32 m; P < 0.01). Table 2 displays results of the interactions between treatment group assignment and BMI status across all outcomes measures. On the primary outcome measure of global FM symptom severity (ie, FIQ), the interaction between treatment group assignment and obesity was significant (P = 0.02). Specifically, in the nonobese group, MI was associated with a greater reduction in FIQ than AC (Fig. 1A) Among the secondary outcome measures, only BPI pain intensity showed statistically significant interaction between treatment group assignment and obesity (P = 0.01). Among nonobese participants, MI was associated with greater reduction in BPI pain intensity compared with the AC group (Fig. 1B) . The reverse was true in the obese group. In the latter group, MI participants reported less reduction in BPI pain intensity compared with AC participants.
Although the interaction analyses for both the 6MWT and physical activity (CHAMPS) were not statistically significant (P = 0.17 and 0.54, respectively), the subset analyses showed interesting findings. Among the nonobese participants, MI participants significantly increased walking distance at the 6-month follow-up (56 ± 10 m) compared with the AC group (25 ± 9 m; P = 0.02). In the obese group, the change in walking distance was not different between MI and AC (P = 0.58). For CHAMPS, the treatment group difference (in favor of MI over AC) with regards to the amount of light-moderate physical activity was greater among nonobese participants (D = 1.96 ± 1.64 h/wk) compared with the obese subset (D = 0.61 ± 1.51 h/wk), albeit the difference was not statistically significant.
DISCUSSION
This is the first study to demonstrate that obese and nonobese participants with FM show posttreatment differences to MI, suggesting that nonobese participants respond better to MI compared with their obese counterparts. Among those receiving MI, improvement in global FM symptom severity (FIQ) and pain intensity (BPI) was greater in participants with BMI < 30 kg/m 2 . Although the interaction of treatment group assignment and obesity status was not statistically significant for physical activity (CHAMPS), the treatment group difference favoring MI (over AC) was larger among nonobese participants compared with obese participants (mean increase, 2 h/wk vs. mean increase, 37 min/wk). In addition, MI was associated with a statistically significant increased walking distance, but only in the nonobese subset of the cohort.
Evidence of an association between obesity and FM continues to grow, yet the mechanisms linking obesity to chronic pain remain unclear. 11 The following obesityrelated factors may contribute to increased pain or chronification of pain: musculoskeletal overload, 35 altered body mechanics/gait, 36 and systemic inflammation. 37 In addition to these biological variables, cognitive factors may also, indirectly or directly, play a role. Several studies have shown that obesity is associated with several cognitive alterations, including negative perceptions about the benefits of exercise and physical activity, 38 less enjoyment during exercise, 39 more profound social stigmatization, 40 and fear of movement. 41 Obese patients with FM often identify a greater number of barriers to performing health promoting behaviors and report lower self-efficacy for performing physical activity. 9 Moreover, obese persons frequently describe exercise as uncomfortable and unpleasant, which in turn, often leads to activity avoidance. 42, 43 Thus, while exercise and physical activity have the potential to improve pain symptoms and physical function, the confluence of weight-related discomfort and additional Bold P values are statistically significant. *P < 0.05 cognitive distractors may have rendered exercise-based MI ineffective among obese participants compared with their nonobese counterparts. Light-moderate intensity physical activity is effective in reducing pain symptoms in patients with FM. 44 In the current study, nonobese participants receiving MI reported a greater increase in light-moderate physical activity (mean increase, E2 h/wk) compared with obese participants receiving MI (mean increase, E37 min/wk). Although this posttreatment difference was not statistically significant (partly due to the wide confidence intervals of CHAMPS), our findings are likely clinically relevant. Despite public health recommendation to engage in at least 150 minutes of moderate-intensity physical activity each week, 45 it is becoming increasingly recognized that even small doses of physical activity (ie, reduced frequency, intensity, and/or duration) can confer significant health benefits. 46 A recent systemic review of older adults has found that low intensity exercise is effective in improving several aspects of health pertinent to patients with FM, including muscular strength, flexibility, balance, depressive symptoms, and fall risk. 47 Furthermore, previous research has shown that increase in exercise capacity is predictive of improvement in cognition, 48 and that exercise bouts as short as 10 minutes are associated with significant improvement in psychological distress. 49 In light of this evidence, we speculate that MI may have been more effective in improving psychological outlook and motivation to be more physically active in nonobese patients with FM. This inference is strengthened by our finding that MI was associated with a significantly greater increase in exercise capacity (6MWT) in nonobese participants (P = 0.02) compared with their obese counterparts (P = 0.58).
The results of this study must be considered in the context of several limitations. First, given that the current report was a post hoc analysis of a previously completed randomized clinical trial, it is possible that our study findings could have occurred by chance alone and/or from a sample size that was inadequate to fully assess interaction effects. However, there are biological and psychological models to support the moderating effect of obesity on treatment success. Second, our study population consisted primarily of women reporting higher levels of pain. Thus, the extent to which these findings extend to men with FM, or those reporting less severe pain symptoms, is unclear. However, the clinical characteristics of the current study participants are comparable with other psychoeducationalbased clinical trials in FM. 50 Finally, the present study focused solely on the influence of obesity and not on other comorbid conditions commonly associated with excessive weight gain (eg, cardiovascular disease, chronic lung disease, depression). Given that the current study excluded participants with cardiovascular disease and chronic lung disease, the moderating effects of these 2 medical conditions cannot be evaluated. Interestingly, depression, another common comorbid condition in FM, was not a treatment moderator in our study (data not shown). Despite these limitations, the strengths of this study include its longitudinal design, large sample size, longer study duration, and low dropout rate (18/216 = 8.3%).
CONCLUSIONS
This is the first study to investigate the influence of obesity on a psychological intervention designed to improve clinical outcomes in FM. Our findings suggest that obesity negatively influences the ability of MI to improve global FM symptom severity and pain, and may contribute to reduced physical activity, in patients with FM. Obesity that coexists with FM may serve as a barrier to the effectiveness of MI designed to improve physical activity and clinical outcomes in individuals with FM. Future studies should examine the clinical effectiveness (including cost benefit analyses) of behavioral interventions that combine physical activity and weight management counseling on clinical outcomes in patients with FM. Although our study findings need to be replicated in larger, more diverse samples, the results from this study can assist clinician decision-making regarding the role of exercise-based MI in the treatment algorithm for patients with FM.
